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Abstract
Loss of body protein and hyperglycaemia represent typical features of the stress response to surgery and anaesthesia. This appears to be
particularly pronounced in patients with diabetes mellitus type 2. The aim of the present study was to highlight the greater benefit of amino
acids (AA) as represented by positive protein balance and maintenance of blood glucose homoeostasis compared with dextrose (DEX) in
diabetic patients after colorectal surgery. A total of thirteen patients underwent a 5 h stable isotope infusion study (2 h fasted, 3 h fed with
an infusion of AA (n 6) or DEX (n 7)) on the second post-operative day. Glucose and protein kinetics were assessed by using the stable
isotopes L-[1-13C]leucine and [6,6-2H2]glucose. The transition from fasted to fed state decreased endogenous glucose production (P,0·001)
in both groups, with a more profound effect in the DEX group (P¼0·031). In contrast, total glucose production was increased by the pro-
vision of DEX while being lowered by AA (P¼0·021). Feeding decreased protein oxidation (P¼0·009) and protein synthesis in the AA
group, whereas DEX infusion did not affect oxidation and even decreased protein synthesis. Therefore, only AA shifted protein balance
to a positive value, while patients in the DEX group remained in a catabolic state (P,0·001). Parenteral nutritional support with AA rather
than with DEX is an effective strategy to achieve a positive protein balance while maintaining normoglycaemia in diabetic patients after
colorectal surgery.
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Surgical injury provokes an endocrine metabolic stress
response(1) inducing increased levels of stress hormones
(cortisol, adrenaline, noradrenalin and glucagon) and
decreased secretion and peripheral action of insulin(2). This
pathway causes a catabolic state including stereotypical meta-
bolic alterations such as hyperglycaemia, enhanced lipolysis,
increased muscle protein breakdown and amino acid (AA)
oxidation(3). Since insulin resistance appears to play a role in
these metabolic changes as well as in diabetes mellitus type 2
(DM2), it has been suggested that the catabolic stress responses
to surgery may be exaggerated in DM2 patients(4,5).
Malnutrition in surgical patients is associated with higher
rates of morbidity and mortality(6). These concerns are
emphasised in the population of diabetic patients undergoing
gastrointestinal surgery, as they suffer from higher risk per se
due to their metabolic disorder and the type of surgery.
Protein losses induced by the stress response to surgery can
be attenuated by total parenteral nutrition, but only starving
or malnourished patients with cancer benefit in the sense of
a shift to anabolism(7). Unselected iso- or hyperenergetic
nutritional support in well-nourished surgical patients has no
evidence-based indication and may even cause harm, as it is
associated with increased morbidity(8). Traditional strategies
for patients after gastrointestinal surgery include fasting and
intravenous fluids with hypoenergetic dextrose (DEX) until
bowel motility is secured. However, hyperglycaemic levels,
as possibly induced by DEX infusion, affect the immune
system leading to an increased risk of infection and are related
to an increased risk of post-operative complications in cardiac
surgery(9).
A previous study focusing on the metabolic response of
patients with DM2 to major abdominal surgery reported
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marked protein catabolism as reflected by an increased
oxidative protein loss in patients with DM2 compared with
non-diabetics(4). Although infusing DEX (4 mg/kg per min)
did not affect protein metabolism in either group, plasma
glucose levels were higher and endogenous glucose
production was suppressed to a lesser extent in diabetic
patients(4). The provision of even low-dose DEX was accom-
panied by hyperglycaemia(10,11), which has been associated
with higher perioperative complication rates(9). Therefore,
subsequent trials provided nutritional support including AA
with the goal of achieving a protein-sparing effect while
maintaining normoglycaemia(12,13). This anabolic effect of
AA has been shown to be pronounced in diabetic patients
receiving perioperative epidural analgesia compared with
patient-controlled analgesia with morphine(12), reinforcing
the concept that the type of analgesia could be of importance
in modulating the catabolic response to surgery(14).
Based on these separately reported findings in diabetic
patients(4,12), it was decided to analyse the data sub-sets of
the diabetic groups having epidural analgesia from two
previous investigations in order to directly compare the two
nutritional support regimens based on the administration of
AA v. DEX. The aim of the present study was to highlight
the greater benefit of AA as represented by positive protein
balance and maintenance of blood glucose homoeostasis
compared with DEX alone in the vulnerable population of
DM2 patients.
Methods
Patients
A total of thirteen patients with DM2 undergoing elective
colorectal surgery, recruited in two previous studies conduc-
ted at the McGill University Health Centre, Montreal, Canada,
were analysed. With the approval of the Ethics Committee of
the Montreal General Hospital, written informed consent
was obtained from six patients in the AA group(12), and with
the approval of the Ethics Committee of the Royal Victoria
Hospital, Montreal, Canada written informed consent was
obtained from seven patients in the DEX group(4).
Inclusion criteria for both groups were age . 18 years, DM2
(controlled by diet, oral hypoglycaemic medication or insulin)
and colorectal surgery for non-metastatic disease (including
right, transverse, left, sigmoid, subtotal, total and hemicolect-
omy and low anterior resection). Exclusion criteria were
severe cardiac, hepatic, renal or metabolic disorders, diabetes
mellitus type 1, plasma albumin concentration ,35 g/l, more
than 10 % weight loss over the preceding 3 months, anaemia
(haematocrit ,30 %), use of steroids, previous spinal surgery
limiting the use of an epidural catheter and pregnancy.
All patients received general anaesthesia combined with
perioperative epidural analgesia.
Anaesthesia and perioperative care
The patients underwent bowel preparation on the day before
surgery and were allowed to drink clear fluids until midnight.
The patients were operated during the morning hours by one
of three surgeons who were informed of the study protocol.
Oral hypoglycaemic medications were discontinued on the
day of surgery. Perioperative glycaemic control was achieved
by an insulin sliding scale aiming to maintain blood glucose
levels between 5 and 10 mmol/l. Blood glucose was measured
every 6 h. General anaesthesia was standardised: propofol/
thiopentone, fentanyl and rocuronium were used for induc-
tion and anaesthesia was maintained with nitrous oxide in
oxygen and desflurane or isoflurane at end-tidal concen-
trations required to keep heart rate and blood pressure
within 20 % of pre-operative values.
An epidural catheter was inserted between thoracic
vertebral levels T8–T11 before the induction of general anaes-
thesia. Neuraxial blockade was established with 0·5 % bupiva-
caine to achieve a bilateral sensory block from thoracic
dermatome level 4 to sacral dermatome level 1. The blockade
was maintained with an additional administration of 0·25 %
bupivacaine (5–10 ml boluses) during surgery. The sensory
block from dermatomes T8 to L3 was post-operatively main-
tained for at least 48 h by continuous epidural infusion of
0·1 % bupivacaine supplemented with 2mg/ml fentanyl. Pain
levels at rest, during mobilisation and coughing were evalu-
ated in all patients using an eleven-point visual analogue
scale (0, no pain; 10, excruciating pain) every 4 h after surgery.
Pain treatment was adjusted to achieve a visual analogue score
level ,2 at rest and ,5 during mobilisation or coughing.
All patients received hypoenergetic DEX (5 % in 1/4 normal
saline) on the first post-operative day until midnight
when the infusion was changed to normal saline until the
study period.
Experimental protocol
Beginning at 08.00 hours on the second day after surgery
following overnight fasting and receiving only 0·9 % normal
saline from midnight on, the patients underwent a 5 h tracer
kinetic study to characterise protein and glucose metabolism.
The study consisted of a 2 h fasted state, which was followed
by a 3 h fed state (Fig. 1). Plasma kinetics of leucine
and glucose were determined using tracer quantities of
L-[1-13C]leucine (99 % 13C) and [6,6-2H2]glucose (99 %
2H)
(Cambridge Isotope Laboratories, Cambridge, MA, USA).
Sterile solutions of isotopes were prepared in the hospital
pharmacy and kept at 48C until administration. Blood and
expired breath samples were collected to determine baseline
isotopic enrichments. Each blood sample was transferred
immediately to a heparinised tube, centrifuged at 48C
(2400 g £ 10 min) and stored at 2708C. Breath samples were
collected in a 2 litre latex bag and transferred immediately
to 10 ml vacutainers (BD Vacutainer, Becton Dickinson,
Franklin Lakes, NJ, USA). Sodium bicarbonate (NaH13CO3;
0·08 mg/kg) was administered orally. Priming doses of
L-[1-13C]leucine (4mmol/kg) and [6,6-2H2]glucose (22mmol/kg)
were injected and followed immediately by continuous
infusions of L-[1-13C]leucine 0·06mmol/kg per min and
[6,6-2H2]glucose 0·22mmol/kg per min lasting for 2 h (fasted
state). For the subsequent 3 h period of the fed state, the
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concentration of L-[1-13C]leucine increased to 0·12mmol/kg
per min and that of [6,6-2H2]glucose was maintained at
0·22mmol/kg per min in the AA group, whereas the concen-
tration of [6,6-2H2]glucose increased to 0·44mmol/kg per min
and that of L-[1-13C]leucine was maintained at 0·22mmol/kg
per min in the DEX group. During the fed state, a solution
of crystallised beet sugar (10 % DEX anhydrous; Avebe,
Foxhol, The Netherlands) was infused at 4 mg/kg per min in
the DEX group. Patients in the AA group received a 10 % AA
solution(13) without electrolytes (Travasole, Baxter, Montreal,
Canada) at a rate of 0·02 ml/kg per min (equivalent to 2·9 g/kg
per d) to achieve plasma AA concentrations at least two-fold
above basal concentrations(15). Both infusion rates are based
on the European Society of Parenteral and Enteral Nutrition
guidelines for protein and glucose intake(16). Towards the
end of each study period, four blood and breath samples
were collected at 10 min intervals, when the tracers were
assumed to have reached an isotopic steady state. Additional
blood samples were drawn during the last 10 min of the
fasted- and fed-state periods for the analysis of glucose, insu-
lin, glucagon and cortisol. Indirect calorimetry (Vmax 29N;
SensorMedics, Yorba Linda, CA, USA and Datex Deltatrac,
Helsinki, Finland) was performed for 15 min in the last hour
of the fasted and fed states of each tracer kinetic study
period. The patients lay in a semi-recumbent position and
breathed room air in a ventilated tent. Whole-body oxygen
consumption (VO2) and carbon dioxide production (VCO2)
were used to calculate respiratory quotient. Average values
were used accepting a CV of less than 10 % over 10 min(10).
Measurements
Isotopic enrichments. Isotopic enrichment of plasma
[1-13C]a-ketoisocaproate, representing the intracellular leucine
pool, was used as the basis for calculating both leucine flux
and the appearance from protein breakdown, as described
previously(17). a-Ketoisocaproate enrichment and plasma
[6,6-2H2]glucose enrichment were analysed by GC–MS
(17,18).
Plasma metabolites and hormones. Plasma glucose, serum
insulin, glucagon and plasma cortisol were measured and ana-
lysed as described previously(4,12).
Calculation of protein and glucose metabolism. Whole-
body leucine and glucose kinetics were determined by
conventional isotope dilution practice applying a two-pool
stochastic model during steady-state conditions of the fasted
and fed states after surgery(4). The kinetics of the AA leucine,
which makes up for 8 % of whole-body protein, are represen-
tative of the dynamics of protein metabolism in the present
study setting. Therefore, the terms ‘protein synthesis’ and
‘protein balance’ represent leucine kinetics and are used to
present and discuss protein metabolism.
Under steady-state conditions, leucine flux (Q) is defined by
the formula: Q ¼ S þ O ¼ B þ I, where S is the rate at which
leucine is incorporated into the body protein, O is the rate
of leucine oxidation, B is the rate at which unlabelled leucine
enters the free AA pool from endogenous protein breakdown
and I is the rate of leucine intake including the tracer (rate of
infusion of L-[1-13C]leucine; mmol/kg per h) and diet. The
calculation of the values for glucose and protein metabolism
was performed as described previously(13).
Statistical analysis
The longitudinal data with one independent factor ‘type of
feeding’ and two time points (fasted v. fed) were analysed
with a Brunner–Langer model with an ANOVA-type statistic.
Statistical analyses were conducted using the SAS System 9.1
(SAS Institute, Cary, NC, USA). A significance level of 0·05
was used for all tests.
Results
Patients
There were no significant differences regarding sex, age,
height, weight, BMI and duration of surgery in both groups
(Table 1). The pain scores measured by the visual analogue
scale never exceeded the value of 4, and no patient com-
plained about severe pain.
Glucose and protein kinetics
Fasting glucose kinetics were comparable in both groups
(Table 2). The main effect of feeding was to decrease
endogenous glucose production (endogenous rate of appear-
ance (Ra) of glucose; P,0·001). The transition from fasted to
Postoperative fast and feeding metabolism (08.00 hours 2 d after surgery)
Fasted Amino acids/dextrose
Primed continuous infusion of  [1-13C]leucine and [6,6–2H2]glucose
0 150 160 170 180 330 340 350 360 min
ø ø ø ø ø ø ø ø ø
x x
Fig. 1. Time course of the infusion of isotopes and collection of plasma and expired air samples (Ø) performed by indirect calorimetry (h), and collection of
plasma for the determination of metabolic substrates and hormones ( £ ) in the fasted state and during the infusion of amino acids.
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fed state lowered the endogenous Ra of glucose to a greater
extent in the DEX group compared with that in the AA
group (P¼0·031), whereas total glucose production (total Ra
of glucose) was higher in the DEX group compared with the
AA group (P¼0·021). DEX infusion decreased the endogenous
Ra of glucose dramatically while increasing the total Ra of
glucose. In contrast, AA infusion decreased both endogenous
Ra and total Ra of glucose (P¼0·034 and P,0·001, respect-
ively). The transition from fasted to fed state decreased
glucose clearance (P,0·001), with a more profound effect
for the AA group (P¼0·003).
Fasting AA kinetics (Table 3) were similar in both groups
except for leucine oxidation (DEX group: 29 (SD 9)mmol/kg
per·h; AA group: 15 (SD 5)mmol/kg per h; P¼0·005), resulting
in a less negative protein balance in the AA group compared
with the DEX group (DEX group: 229 (SD 9)mmol/kg per h;
AA group: 215 (SD 5)mmol/kg per h). The main effect of
feeding was a decrease in endogenous Ra of leucine
(P¼0·016). The type of nutrition had a greater impact on leu-
cine oxidation in the AA group, showing an increase when
compared with the constant values in the DEX group
(P¼0·009). The infusion of AA, therefore, shifted protein bal-
ance to a positive value, whereas patients in the DEX group
remained in a net catabolic state (P¼0·025). This contrasting
effect was mainly attributed to the type of feeding (P,0·001).
Gaseous exchange
Gaseous exchange values were comparable for the groups in
the fasted state. No significant changes were observed by the
effect of nutrition or type of nutrition (Table 4).
Plasma hormones and metabolites
Hormones and metabolites (Table 5) were also affected by
feeding. Feeding increased plasma glucose (P,0·001) and
insulin (P¼0·009), resulting in hyperglycaemia in the DEX
group and normoglycaemia in the AA group (P¼0·063 for
the type of feeding and P¼0·001 for the interaction). Feeding
provoked an increase in glucagon in the AA group and a
decrease in the DEX group (P¼0·03). The insulin:glucagon
ratio increased to a greater extent during DEX infusion com-
pared with AA provision (P¼0·013). When using the homo-
eostasis model assessment (HOMA) to account for insulin
sensitivity, feeding increased the HOMA values in both
groups (P,0·001).
Discussion
The present results suggest that an intravenous infusion of AA
prevents pronounced hyperglycaemia in diabetic patients after
colorectal surgery. This is in accordance with the state of insu-
lin resistance observed in patients with diabetes mellitus,
resulting in limited suppressibility of endogenous glucose pro-
duction and abnormal peripheral glucose utilisation(19). Fur-
thermore, a positive protein balance can be achieved,
whereas DEX infusion alone does not affect protein metab-
olism and the patients remain in a net catabolic state.
Endogenous glucose supply is based on glycogenolysis and
gluconeogenesis. Overnight fasting leads to post-absorptive
Table 2. Kinetics of glucose metabolism in the fasted and fed state for the dextrose (DEX) and amino acid (AA) groups
(Mean values and standard deviations, n 7 for the DEX group and n 6 for the AA group)
DEX AA
Fasted Fed Fasted Fed P
Variable Mean SD Mean SD Mean SD Mean SD
Feeding
state*
Type of
nutrition† Interaction‡
Endogenous rate of appearance
of glucose (mmol/kg per min)
15·3 2·1 3·9 1·2 17·3 3·3 12·2 3·2 ,0·001 0·031 0·034
Total rate of appearance of
glucose (mmol/kg per min)
15·3 2·1 24·6 1·8 17·3 3·3 12·2 3·2 0·069 0·021 , 0·001
Glucose clearance (ml/kg per min) 2·1 0·5 1·8 0·4 2·4 0·4 1·6 0·3 , 0·001 0·917 0·003
* Probability that values are influenced by parenteral alimentation.
† Probability that values are influenced by the type of nutrition.
‡ Probability that the effect of type of nutrition is greater in one group.
Table 1. Demographic data of patients
(Mean values and standard deviations)
Amino acids Dextrose
Mean SD Mean SD
Number of patients 6 7
Age (years) 74 9 68 5
Height (cm) 173 11 167 7
Weight (kg) 86·5 21·8 70·9 5·4
BMI (kg/m2) 28·9 5·8 25·4 1·8
Sex
Male 5 4
Female 1 3
ASA (I/II/III)
I 0 0
II 3 4
III 3 3
Type of surgery
Hemicolectomy/colectomy 2 3
Anterior resection 4 4
Duration of surgery (min) 167 93 214 57
Type of diabetes treatment
Diet 1 2
OAD 4 5
Insulin 1 0
ASA, American Society of Anesthesiologists classification; OAD, oral anti-diabetic
drugs.
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conditions, where glycogenolysis and gluconeogenesis each
provide about half of the whole-body glucose production(20).
With ongoing fasting, gluconeogenesis increases gradually
and contributes up to 90 % of glucose production after 42 h
in non-diabetic patients(21). In a more moderate manner, these
adaptations are also observed in patients with DM2(5,22) and
in well-nourished patients with malignant diseases(23). The
present findings are consistent with these reports, as the
endogenous Ra of glucose is about 35 % higher in diabetic
patients compared with that in non-diabetic patients in
post-absorptive conditions(10,11,13). The inhibitory effect of
exogenous glucose on endogenous glucose production
depends on the amount of glucose infused and the patient’s
metabolic state. This is also reflected by a reduced suppression
of endogenous glucose production in septic or traumatised
patients(24,25). Furthermore, altered glucose homoeostasis
predisposes hyperglycaemic myocardial tissue to injury
during ischaemia, and insulin resistance has been shown to
be an independent risk factor of in-hospital mortality following
acute myocardial infarction(26). It must be noted that such a
reduction in endogenous glucose production due to exogenous
administration of glucose is most pronounced in post-operative
diabetic patients(4). In general, AA infusion during the
post-operative period effectively reduces endogenous glucose
production in non-diabetic patients(13,27). In the present study,
this reduction in endogenous glucose production in diabetic
patients due to AA infusion was more pronounced than
previously reported in non-diabetic patients(13). Therefore, it
may be hypothesised that AA infusion suppresses the endogen-
ous rate of appearance of leucine, i.e. proteolysis, because less
AA are required for gluconeogenesis independent of the effect
of insulin.
The anti-catabolic effect of insulin depends on the state of
peripheral resistance, mainly through the inhibition of
muscle protein breakdown(28). In patients with diabetes melli-
tus type 1, protein breakdown and oxidation are increased,
whereas in DM2 patients with good or moderate glucose con-
trol, the rate of appearance of leucine and protein breakdown
is normal(29). Furthermore, in poorly controlled and obese
DM2 patients, protein breakdown was higher than in their
non-diabetic counterparts(30), and leucine oxidation has not
been shown to be increased(5). In the fasted state, discrepant
results regarding leucine oxidation were detectable, as the
DEX group clearly showed higher leucine oxidation compared
with previously published results in non-diabetic patients,
whereas this value was slightly lower in the AA group than
in non-diabetic patients(10,11,13). A possible explanation and
limitation of the present study was not having determined
HbA1c before surgery. However, the pre-operative plasma
glucose concentrations indicated good or moderate control
in both groups. A previous study reported that hyperglucago-
naemia appears to be primarily responsible for increased
leucine oxidation in diabetes type 1 patients(31). However,
glucagon levels during the fasted state were comparable in
Table 3. Kinetics of protein metabolism in the fasted and fed state for the dextrose (DEX) and amino acid (AA) groups
(Mean values and standard deviations, n 7 for the DEX group and n 6 for the AA group)
DEX AA
Fasted Fed Fasted Fed P
Variable (mmol/kg per h) Mean SD Mean SD Mean SD Mean SD Feeding state* Type of nutrition† Interaction‡
Rate of appearance of Leu 133 26 120 15 123 19 142 25 0·832 0·507 0·128
Endogenous rate of appearance of
Leu (net protein breakdown)
133 26 120 15 123 19 88 25 0·016 0·126 0·118
Leu oxidation 29 9 29 5 15 5 24 8 0·041 0·009 0·16
Protein synthesis of Leu 104 21 92 16 108 19 117 21 0·926 0·136 0·116
Protein balance of Leu 229 9 229 5 215 5 30 8 0·12 , 0·001 0·025
* Probability that values are influenced by parenteral alimentation.
† Probability that values are influenced by the type of nutrition.
‡ Probability that the effect of type of nutrition is greater in one group.
Table 4. Gaseous exchange in the fasted and fed state for the dextrose (DEX) and amino acid (AA) groups
(Mean values and standard deviations, n 7 for the DEX group and n 6 for the AA group)
DEX AA
Fasted Fed Fasted Fed P
Variable Mean SD Mean SD Mean SD Mean SD Feeding state* Type of nutrition† Interaction‡
VO2 (ml/min) 252 54 242 46 262 27 295 78 0·888 0·188 0·417
VCO2 (ml/min) 189 41 183 35 194 26 209 50 0·756 0·399 0·328
RQ 0·75 0·02 0·76 0·02 0·74 0·05 0·72 0·11 0·845 0·281 0·38
VO2, oxygen consumption; VCO2, carbon dioxide production; RQ, respiratory quotient.
* Probability that values are influenced by parenteral alimentation.
† Probability that values are influenced by the type of nutrition.
‡ Probability that the effect of type of nutrition is greater in one group.
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both groups. Additionally, it could be argued that the
DEX group included patients with a wider range of insulin
sensitivity as represented by homoeostasis model assessment
(HOMA) in the fasted state.
The relative concentrations of insulin and glucagon control
the hepatic glucose balance(32). The insulin:glucagon ratio is
inversely correlated with increased glucose production in
the liver. A high ratio indicates glucose storage and increased
protein synthesis, whereas a low ratio is a sign of increased
gluconeogenesis from AA. In a previous study, comparing
diabetic patients with non-diabetic patients after colorectal
surgery, lower insulin concentrations were found to be
accompanied by higher glucagon levels in the diabetic
group. Furthermore, negative correlations between the insu-
lin:glucagon ratio and glucose production as well as AA
oxidation led to the conclusion that these changes might be
attributed to alterations in the insulin:glucagon system(4).
The present study revealed higher levels of insulin in the
fasted as well as in the fed state for the DEX group, whereas
glucagon decreased in the DEX group and increased in the
AA group during feeding, resulting in a higher insulin:gluca-
gon ratio in patients of the DEX group.
Infusion of AA increased the Ra of leucine, leucine oxi-
dation, as well as protein synthesis accompanied by a reduced
net protein breakdown, resulting in a positive protein balance.
In contrast, the administration of DEX did not affect protein
kinetics, and the protein balance remained negative in the
fed state. The patients receiving AA showed a net leucine bal-
ance in the fed state that was 59mmol/kg per h higher than in
the patients receiving glucose. Assuming body protein con-
tains 8 % leucine, this translates to savings of 140 g protein
in a 70 kg person in 1 d. The potential impact on lean body
mass and functional outcomes in post-operative patients was
not assessed in the present study. However, the present find-
ings are consistent with the observations in non-diabetic
patients, although the protein balance even appears to be
improved to a greater extent in diabetic patients(13). With
regard to post-operative morbidity and mortality, a previous
large clinical trial indicated no justification of routine protein-
sparing therapy for normonourished or mildly malnourished
patients undergoing major abdominal surgery(33). However,
the present study included an oral starvation period of 5 d in
a heterogeneous cohort and lacks both a metabolic analysis
and the inclusion of diabetic patients. Taking into account
the evolution of today’s clinical practice promoting a fast
track approach with early oral feeding, future studies focusing
on lipid metabolism, early post-operative feeding and pro-
vision of micronutrients and immunonutrition might offer
additional insight into the optimal perioperative nutritional
support.
In summary, the present study of two types of feeding in
diabetic patients after colorectal surgery underscores the ana-
bolic benefits of AA while possibly preventing hyperglycae-
mia-induced comorbidities associated with DEX infusion.
Therefore, a peripheral intravenous provision of AA in a peri-
operative setting of major abdominal surgery in diabetic or
malnourished patients with only short oral fasting periods
might be considered to improve nutritional support of theseT
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patients. However, the perioperative provision of AA with
respect to improved outcomes in clearly defined patient
groups requires further investigation.
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